Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory of Diagnosis and Therapy of Lysosomal Disorders, |
RCV000677617 | SCV000803135 | pathogenic | Mucopolysaccharidosis type 6 | 2018-01-01 | criteria provided, single submitter | curation | Nonsense variant (PVS1); In vitro functional studies supportive of a damaging effect on the gene product (low to no ARSB activity in homozygotes; PS3); Very low frequency in ExAc (PM2); Reputable source identifies as pathogenic (PP5) |
Molecular Diagnostics Laboratory, |
RCV000677617 | SCV000891256 | pathogenic | Mucopolysaccharidosis type 6 | 2018-10-03 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000677617 | SCV002234824 | pathogenic | Mucopolysaccharidosis type 6 | 2023-12-20 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg327*) in the ARSB gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ARSB are known to be pathogenic (PMID: 17458871, 22133300). This variant is present in population databases (no rsID available, gnomAD 0.003%). This premature translational stop signal has been observed in individual(s) with mucopolysaccharidosis type VI (PMID: 14974081, 23557332). ClinVar contains an entry for this variant (Variation ID: 559832). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV000677617 | SCV002788798 | pathogenic | Mucopolysaccharidosis type 6 | 2021-08-06 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000677617 | SCV004210014 | pathogenic | Mucopolysaccharidosis type 6 | 2022-10-15 | criteria provided, single submitter | clinical testing | |
Department Of Genetics, |
RCV000677617 | SCV000891628 | pathogenic | Mucopolysaccharidosis type 6 | 2017-12-30 | no assertion criteria provided | curation |